July 29, 2022

Advances in gene therapy delivery: a non-viral pDNA platform that harnesses the power of IL-10

Advances in gene therapy delivery: a non-viral pDNA platform that harnesses the power of IL-10

Using cytokines therapeutically is like firing a shotgun at range – for sure you will hit your target, but off-target effects are likely, if not certain. To hit your target exclusively you have to get close. Delivering a proprietary version of the chronic inflammatory cytokine IL-10 encoded on a proprietary plasmid, injected locally, gets you really close. Using their non-viral, non-integrating vector, Xalud Therapeutics is exploring the use of IL-10 for osteoarthritis (FDA fast tracked), and other chronic inflammatory conditions, including ALS, MS, and neuropathic pain, with data from over 300 OA patients already in hand.